4//SEC Filing
Shenouda Maged 4
Accession 0001213900-25-046087
CIK 0001553643other
Filed
May 19, 8:00 PM ET
Accepted
May 20, 6:03 PM ET
Size
8.7 KB
Accession
0001213900-25-046087
Insider Transaction Report
Form 4
Shenouda Maged
Chief Financial Officer
Transactions
- Purchase
Common Stock
2025-05-16$0.44/sh+50,000$22,100→ 138,335 total - Purchase
Common Stock
2025-05-20$0.52/sh+60,000$31,422→ 288,335 total - Purchase
Common Stock
2025-05-19$0.49/sh+90,000$43,686→ 228,335 total
Footnotes (4)
- [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- [F2]Purchase prices range from $0.4229 to $0.4674 per share, inclusive.
- [F3]Purchase prices range from $0.4493 to $0.4998 per share, inclusive.
- [F4]Purchase prices range from $0.4998 to $0.5396 per share, inclusive.
Documents
Issuer
RELMADA THERAPEUTICS, INC.
CIK 0001553643
Entity typeother
Related Parties
1- filerCIK 0001658369
Filing Metadata
- Form type
- 4
- Filed
- May 19, 8:00 PM ET
- Accepted
- May 20, 6:03 PM ET
- Size
- 8.7 KB